Sterberisiko für Mundhöhlen- und Oropharynxkarzinome in Thüringen: eine bevölkerungsbasierte Analyse

Zusammenfassung

Hintergrund Diese populationsbezogene Studie untersuchte den Einfluss der HPV-Assoziation auf das Gesamtüberleben (OS) von Mundhöhlen- (OSCC) und Oropharynxkarzinomen (OPSCC) in Thüringen und die Inzidenz der HPV-positiven (HPV+) und HPV-negativen (HPV-) Tumoren.

Methoden Insgesamt wurden alle 308 Thüringer Patienten (83,4 % Männer; medianes Alter 58 Jahre) mit der Erstdiagnose eines OSCC (38%) oder OPSCC (62%) aus dem Jahr 2008 in die Studie aufgenommen. Nach der Risikoklassifikation nach Ang wurden Patienten in ein geringes Sterberisiko (HPV+, Nichtraucher), intermediäres Risiko (HPV+, Raucher) und hohem Sterberisiko (HPV-, Raucher) eingeteilt. Kaplan-Meier-Analysen und eine multivariable Regressionsanalyse nach Cox wurden durchgeführt, um das OS zu untersuchen.

Ergebnisse 22,5% der OPSCC war HPV+ (davon 80,1% Raucher; Inzidenz: 1,89/100.000 Einwohner). Bei OSCC lag der Anteil der HPV+ bei 8,5% (davon 78,6% Raucher; Inzidenz: 0,44/100.000). Der mediane Follow-up betrug 31 Monate. HPV+ Patienten hatten eine signifikant bessere 5-Jahres-OS als HPV-Patienten (81 % vs. 49 %; p < 0,001). In der multivariablen Analyse ergab sich ein höheres Sterberisiko für: HPV-Patienten (Hazard Ratio [HR] = 3,2; 95%-Konfidenzintervall [KI]: 1,6–6,4; p = 0,001), eine hohe Risikoklasse nach Ang (HR = 2,3; 95%-KI: 1,0–5,4; p = 0,049), höheres Alter (HR = 1,7; 95%-KI = 1,1–2,4; p = 0,01), T3/T4 Tumoren (HR = 2,1; 95%-KI = 1,3–3,2; p = 0,001) und das Vorhandensein von Fernmetastasen (HR = 2,7; 95%-KI = 1,6–4,4; p < 0,001).

Schlussfolgerung HPV+ Nichtraucher waren in Thüringen eine Minderheit. Die Mehrheit der HPV+ Patienten in Thüringen wiesen durch den Nikotinkonsum als Risikofaktor ein intermediäres Sterberisiko auf.

Abstract

Objective This population-based study investigates the impact of HPV association on overall survival (OS) of oral cavity (OSCC) and oropharyngeal squamous cell carcinoma (OPSCC) in Thuringia and the incidence of HPV-positive (HPV+) and HPV-negative (HPV-) tumors.

Methods A total of 308 patients (83.4% men; mean age 57.6 years) with a primary diagnosis of OSCC (38%) or OPSCC (62%) from 2008 were included in the study. Descriptive statistics were obtained for the variables. According to Angʼs risk classification, patients were classified as low risk of death (HPV+, nonsmokers), intermediate risk (HPV+, smokers) and high risk of death (HPV-smokers). Kaplan-Meier analyses and Cox multivariable regression analysis were performed to examine OS.

Results 22.5% of OPSCC was HPV+ (incidence: 1.89/100,000 population; thereof 80.1% smokers). The proportion of OSCC with HPV+ was 8.5% (incidence: 0.44/100,000; thereof 78.6% smokers). The median follow-up was 31 months. HPV+ patients had significantly better 5-year OS than HPV- patients (81% vs. 49%; p < 0.001). In multivariable analysis lower OS were associated with: HPV-patients (hazard ratio (HR) = 3.2; 95% confidence interval (CI) = 1.6–6.4; p = 0.001), high risk of death according to Ang (HR = 2.3; 95% CI = 1.0–5.4; p = 0.049), older age (HR = 1.7; 95% CI = 1.1–2.4; p = 0.01), T3/T4-classification (HR = 2.1; 95% CI = 1.3–3.2; p = 0.001) and the presence of distant metastases (HR = 2.7; 95% CI = 1.6–4.4; p < 0.001).

Conclusions HPV+ non-smokers were minority in Thuringia. The majority of HPV+ patients had an intermediate risk of death due to cigarette smoking.

Schlüsselwörter

Humanes Papillomavirus - Kopf-Hals-Tumoren - Risikostratifizierung - Rauchen - Alkohol - Überleben - Inzidenz

Keywords

human papillomavirus - head and neck cancer - risk stratification - smoking - overall survival - incidence

Publication History

Received: 23 August 2022

Accepted after revision: 10 November 2022

Article published online:
05 January 2023

• Literatur

• 1 Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005; 32 (Suppl. 01) S59-S66
• 2 Gillison ML, Chaturvedi AK, Anderson WF. et al. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol 2015; 33: 3235-3242
• 3 Tinhofer I, Jöhrens K, Keilholz U. et al. Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. Eur J Cancer 2015; 51: 514-521
• 4 Plummer M, de Martel C, Vignat J. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global health 2016; 4: e609-e616
• 5 Wittekindt C, Wagner S, Bushnak A. et al. Increasing Incidence rates of Oropharyngeal Squamous Cell Carcinoma in Germany and Significance of Disease Burden Attributed to Human Papillomavirus. Cancer prevention research (Philadelphia, Pa) 2019; 12: 375-382
• 6 Quabius ES, Haag J, Kühnel A. et al. Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany. International journal of oncology 2015; 46: 414-422
• 7 Wurdemann N, Wagner S, Sharma SJ. et al. Prognostic Impact of AJCC/UICC 8th Edition New Staging Rules in Oropharyngeal Squamous Cell Carcinoma. Frontiers in oncology 2017; 7: 129
• 8 Yete S, D’Souza W, Saranath D. High-Risk Human Papillomavirus in Oral Cancer: Clinical Implications. Oncology 2018; 94: 133-141
• 9 Ndiaye C, Mena M, Alemany L. et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014; 15: 1319-1331
• 10 Hübbers CU, Akgül B. HPV and cancer of the oral cavity. Virulence 2015; 6: 244-248
• 11 Zentrum für Krebsregisterdaten im Robert Koch-Institut: Datenbankabfrage mit Schätzung der Inzidenz, Prävalenz und des Überlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten. Statistisches Bundesamt:. www.krebsdaten.de/abfrage
• 12 Guntinas-Lichius O, Wendt T, Buentzel J. et al. Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. Journal of Cancer Research and Clinical Oncology 2010; 136: 55-63
• 13 Dittberner A, Friedl B, Wittig A. et al. Gender Disparities in Epidemiology, Treatment, and Outcome for Head and Neck Cancer in Germany: A Population-Based Long-Term Analysis from 1996 to 2016 of the Thuringian Cancer Registry. Cancers (Basel) 2020; 12
• 14 Fakhry C, Westra WH, Li S. et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute 2008; 100: 261-269
• 15 Wuerdemann N, Wittekindt C, Sharma SJ. et al. Risk Factors for Overall Survival Outcome in Surgically Treated Human Papillomavirus-Negative and Positive Patients with Oropharyngeal Cancer. Oncol Res Treat 2017; 40: 320-327
• 16 Cornelius ME, Wang TW, Jamal A. et al. Tobacco Product Use Among Adults – United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69: 1736-1742
• 17 Kotz D, Böckmann M, Kastaun S. The Use of Tobacco, E-Cigarettes, and Methods to Quit Smoking in Germany. Dtsch Arztebl Int 2018; 115: 235-242
• 18 Ang KK, Harris J, Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35
• 19 Sobin LH, Gospodarowicz MK, Wittekind C. et al. TNM classification of malignant tumours / edited. In: Sobin LH, Gospodarowicz MK, Wittekind Ch. by . 7th ed. 2009. ed. England: Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell; 2010
• 20 Glombitza F, Guntinas-Lichius O, Petersen I. HPV status in head and neck tumors. Pathology, research and practice 2010; 206: 229-234
• 21 Laco J, Vosmikova H, Novakova V. et al. The role of high-risk human papillomavirus infection in oral and oropharyngeal squamous cell carcinoma in non-smoking and non-drinking patients: a clinicopathological and molecular study of 46 cases. Virchows Archiv : an international journal of pathology 2011; 458: 179-187
• 22 Klussmann JP, Dinh S, Guntinas-Lichius O. et al. HPV-associated tonsillar cancer. An update. Hno 2004; 52: 208-218
• 23 Gillison ML, DʼSouza G, Westra W. et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. Journal of the National Cancer Institute 2008; 100: 407-420
• 24 Wagner S, Wittekindt C, Sharma SJ. et al. Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer. Br J Cancer 2017; 116: 1604-1611
• 25 Julia O. Die Inzidenz oropharyngealer Tumoren in Deutschland im Zeitraum von 1996 bis 2010 unter besonderer Berücksichtigung potentiell HPV-assoziierter Tumorlokalisationen. Universität des Saarlandes; 2018
• 26 Serrano B, Brotons M, Bosch FX. et al. Epidemiology and burden of HPV-related disease. Best practice & research Clinical obstetrics & gynaecology 2018; 47: 14-26
• 27 Combes JD, Chen AA, Franceschi S. Prevalence of human papillomavirus in cancer of the oropharynx by gender. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014; 23: 2954-2958
• 28 Chera BS, Amdur RJ, Green R. et al. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; 37: 2661-2669
• 29 Guntinas-Lichius O, Wendt TG, Kornetzky N. et al. Trends in epidemiology and treatment and outcome for head and neck cancer: a population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry. Oral oncology 2014; 50: 1157-1164
• 30 Huang SH, O’Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Current treatment options in oncology 2017; 18: 40